Amira Pharmaceuticals, Inc.

Panmira Pharmaceuticals, LLC

Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Brickell Biotech, Inc.

Jeannie M Arruda

Thomas Jon Seiders

John Howard Hutchinson

Brian Andrew Stearns

Bowei Wang

Jeffrey Roger Roppe

Nicholas Simon Stock

Deborah Volkots

Jill Melissa Scott

Lucy Xiumin Zhao

Yen Truong

Ryan Christopher Clark

Jean-Michel Andre Vernier

Petpiboon Peppi Prasit

Timothy Andrew Parr

Yiwei Li

Xiumin Zhao

Nicholas D Smith

Benito Munoz

Joseph E Payne

Dehua Huang

Brian Walter Eastman

Heather Renee Coate

Brian T Campbell

Nicholas David Cosford

Mark Moran

Jillian Frances Evans

Steve Fong Poon

Chris King

Mustapha Haddach

Jasmine Eleanor Zunic

Thomas Jonathan Seiders

David Nathan Zalatan

Mark T Bilodeau

Jun Liang

Mark E Layton

Lida R Tehrani

Peter J Manley

Tony Siu

Nicholas D P Cosford

Essa H Hu

Jacob M Hoffman

Celine Bonnefous

Kevin J Rodzinak

Rowena Villanueva Cube

Naomi Burke Anker

Tao Hu

Yem Pham Truong

Yen Pham Truong

Nicholas D Cosford

Timothy Parr

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Polycyclic compounds as lysophosphatidic acid receptor antagonists

Compounds as lysophosphatidic acid receptor antagonists

The identification of a unique series of compounds which possesses special advantages in terms of drug-like properties due to their possessing advantageous properties in terms of potency and/or pharmacokinetic and/or selectivity and/or in vivo receptor occupancy properties. Specifically, the selection of a 1,3-thiazol-2-yl ring member linked by an ethynylene to the 3 position of a pyridyl ring or the 5 position of a pyrimidinyl ring, wherein the ring is substituted with selected substituents, results in a compound having superior drug-like properties. The invention includes pharmaceutically acceptable salt forms of these heterocyclic compounds, in particular chloride salts and trifluoroacetate salts.

Thiazolyl mGluR5 antagonists and methods for their use

A method for treating a human comprises administering a therapeutically effective amount of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid or a pharmaceutically acceptable salt or a pharmaceutically acceptable N-oxide thereof, to the human in need.

5-lipoxygenase-activating protein (FLAP) inhibitors

Described herein are antagonists of PGDreceptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists of PGDreceptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD-dependent or PGD-mediated conditions or diseases.

[object Object]

Described herein are compounds that are antagonists of PGDreceptors. Also described are pharmaceutical compositions and medicaments that include the antagonists of PGDreceptors described herein, as well as methods of using such antagonists of PGDreceptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD-dependent or PGD-mediated conditions or diseases.

Alkyne antagonists of lysophosphatidic acid receptors

Antagonists of lysophosphatidic acid receptors

Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

Described herein are compounds that are antagonists of PGDreceptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGDreceptors. Also described herein are methods of using such antagonists of PGDreceptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD-dependent or PGD-mediated conditions or diseases.

N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors

Polycyclic antagonists of lysophosphatidic acid receptors

Described herein are compounds that are antagonists of PGDreceptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGDreceptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD-dependent or PGD-mediated conditions or diseases.

Growing community of inventors

San Diego, CA, United States of America

Jeannie M Arruda